Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of
the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors:
An open, single and multiple administration, dose escalation, and expanded phase I trial